Concord Biotech

Concord Biotech FCF Margin

The Free Cash Flow Margin of Concord Biotech (CONCORDBIO.NS) as of Oct 18, 2026 is 16.51 %. In the previous year, Free Cash Flow Margin was 11.35 % — a change of 45.40% (higher).

FCF Margin

16.51 %

YoY

45.40%

Last updated:

Free Cash Flow Margin of Concord Biotech is 2026 16.51 % . Free Cash Flow Margin of Concord Biotech was 2025 11.35 % . It decreases by 45.40% higher compared to the previous year.

The Concord Biotech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2020
-0.12 INR
Jan 1, 2021
-6.06 INR
Jan 1, 2022
7.29 INR
Jan 1, 2023
11.83 INR
Jan 1, 2024
17.68 INR
Jan 1, 2025
11.35 INR
Jan 1, 2026
16.51 INR
The Concord Biotech FCF Margin history
YEARFCF MarginYoY
16.51 %+45.40%
11.35 %-35.78%
17.68 %+49.46%
11.83 %+62.27%
7.29 %-220.38%
-6.06 %+4,879.79%
-0.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

Free Cash Flow Margin of Concord Biotech is 16.51 % in 2026.

Free Cash Flow Margin of Concord Biotech changed from 11.35 % to 16.51 %, representing a 45.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Concord Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Concord Biotech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Concord Biotech